Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells
Researchers are highlighting a new immunotherapy approach targeting both glioblastoma cells and their supporting myeloid cells.
📍 The outcome
The story of dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells quieted without a definitive conclusion in the coverage. CAR-T cell therapy was reported to show potential to eliminate aggressive glioblastoma and engineered immunotherapy was said to improve treatment for brain cancer. The treatment was described as a breakthrough in cancer immunotherapy and an experimental treatment that reduces rare cancerous tumours.
Epilogue added 43d ago, after coverage quieted.
What happened
A new CAR-T cell therapy has been developed to treat glioblastoma, an aggressive form of brain cancer. The strategy uses GPNMB-targeting cells to address the tumor directly while simultaneously disrupting the surrounding immune cells that support the cancer's growth.
Coverage from outlets including Northwestern University, McMaster, Nature, and The Telegraph emphasizes the dual-targeting mechanism of this strategy. Reports highlight that the therapy is designed to eliminate tumor cells and their internal fuel sources.
Future developments will focus on the progression of this research as reported by scientific and medical publications. Coverage does not yet specify timelines for human clinical trials.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 46d ago.
Who reported it (15)
- Beeta Benjy: What is the Missing Puzzle Piece of CAR-T Therapy Failure in Solid Tumors? Oncodaily · 47d ago
- Engineered Immunotherapy Improves Treatment for Brain Cancer Labroots · 47d ago
- CAR T Cells Simultaneously Target Glioblastoma and Immune Cells Inside Precision Medicine · 47d ago
- New Therapy Could Target One of the Deadliest Brain Cancers Newsweek · 47d ago
- Community giving powers a UCalgary cancer immunotherapy breakthrough University of Calgary · 47d ago
- New immunotherapy developed at the University of Calgary being used to treat solid cancerous tumours University of Calgary · 47d ago
- U of C-developed experimental treatment reduces rare cancerous tumours Calgary Herald · 47d ago
- With GPNMB, CAR T makes further inroads in solid tumors BioWorld News · 47d ago
- Immunotherapy Strategy Shows Promise for Deadly Brain Cancer Northwestern University · 47d ago
- McMaster-Developed Immunotherapy Strategy Targets Aggressive Brain Tumours and Their Fuel Newswise · 47d ago
- CAR-T cell therapy shows potential to eliminate aggressive glioblastoma News-Medical · 47d ago
- Cytokine-armoured CAR T therapy shows promise against aggressive glioblastoma Labmate-Online · 47d ago
- New immunotherapy strategy targets aggressive brain tumors and their immune cell accomplices Medical Xpress · 47d ago
- Deadliest brain cancer could be treated with immunotherapy The Telegraph · 47d ago
- Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells Nature · 47d ago
Questions people are asking
What is the primary target of this new CAR-T therapy?
The therapy targets glioblastoma tumor cells and their associated myeloid immune cells.
Which organizations are involved in the development?
Northwestern University and McMaster are identified in coverage as institutions contributing to this immunotherapy research.
What specific protein is the CAR-T therapy targeting?
The therapy utilizes GPNMB-targeting CAR-T cells to address the cancer and its microenvironment.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Can long COVID be prevented? Two drugs finally show promise
New research identifies two drugs with potential to prevent long COVID, even as brain scan studies pinpoint damage to dopamine neurons.
New genetic risk factors linked to chronic pain disorder in major study
A landmark study involving 2.5 million individuals has established a clear biological basis for fibromyalgia by identifying specific genetic risk factors.
Prolonged stretching reorganizes tissue scaffolds and uncages cell nuclei
Stretching skin cells reshapes their keratin scaffold, freeing nuclei and sparking fresh debate on cellular mechanics.
CRISPR makes prostate cancer vulnerable to immunotherapy
CRISPR editing turns immune‑cold prostate tumors into immunotherapy targets, sparking a new treatment direction.
Within-patient gene transfer between transiently and chronically infecting bacteria causes extreme antibiotic resistance during lung infections
A newly identified gene transfer mechanism between transient and chronic bacteria is enabling extreme antibiotic resistance in lung infections.
Secrets of birdsongs' 'spectacular diversity' revealed
Researchers have identified a universal structural foundation consisting of eight core elements that underpin the vast variety of global birdsong.